TG Therapeutics, Inc. (NASDAQ:TGTX) Shares Sold by Algert Global LLC

Algert Global LLC lowered its position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) by 52.9% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 49,061 shares of the biopharmaceutical company's stock after selling 55,191 shares during the period. Algert Global LLC's holdings in TG Therapeutics were worth $1,477,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also bought and sold shares of TGTX. Quadrant Capital Group LLC boosted its position in TG Therapeutics by 137.1% in the 4th quarter. Quadrant Capital Group LLC now owns 1,686 shares of the biopharmaceutical company's stock worth $51,000 after purchasing an additional 975 shares in the last quarter. Blue Trust Inc. boosted its position in TG Therapeutics by 24.5% in the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after purchasing an additional 371 shares in the last quarter. Smartleaf Asset Management LLC boosted its position in TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp boosted its position in TG Therapeutics by 460.7% in the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock worth $64,000 after purchasing an additional 1,737 shares in the last quarter. Finally, Synergy Asset Management LLC purchased a new stake in TG Therapeutics in the 4th quarter worth approximately $75,000. Hedge funds and other institutional investors own 58.58% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts have recently issued reports on TGTX shares. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright reiterated a "buy" rating and set a $55.00 target price on shares of TG Therapeutics in a research report on Tuesday, March 4th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat.com, TG Therapeutics currently has a consensus rating of "Moderate Buy" and an average target price of $40.80.

TG Therapeutics Price Performance

NASDAQ TGTX traded up $1.35 during mid-day trading on Monday, hitting $34.99. The stock had a trading volume of 2,839,383 shares, compared to its average volume of 3,021,400. The firm's 50 day moving average is $38.90 and its 200 day moving average is $33.79. TG Therapeutics, Inc. has a twelve month low of $15.16 and a twelve month high of $46.48. The company has a debt-to-equity ratio of 1.27, a current ratio of 4.59 and a quick ratio of 3.91. The stock has a market capitalization of $5.56 billion, a price-to-earnings ratio of -349.87 and a beta of 2.21.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Wednesday, May 7th. The biopharmaceutical company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.19 by ($0.16). TG Therapeutics had a negative net margin of 5.42% and a negative return on equity of 8.32%. The firm had revenue of $120.86 million during the quarter, compared to analyst estimates of $117.07 million. During the same period in the prior year, the company posted ($0.07) earnings per share. The firm's revenue for the quarter was up 90.4% compared to the same quarter last year. Equities research analysts forecast that TG Therapeutics, Inc. will post 0.08 earnings per share for the current fiscal year.

TG Therapeutics Company Profile

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.